sinc
cancer
stem
cell
csc
first
identifi
leukemia
consid
promis
therapeut
target
cancer
therapi
cell
selfrenew
capac
differenti
potenti
contribut
multipl
tumor
malign
recurr
metastasi
heterogen
multidrug
resist
radiat
resist
biolog
activ
csc
regul
sever
pluripot
transcript
factor
nanog
myc
addit
mani
intracellular
signal
pathway
wnt
nuclear
notch
hedgehog
jakstat
janu
kinasesign
transduc
activ
transcript
phosphoinositid
target
rapamycin
tgf
transform
growth
factor
smad
ppar
peroxisom
proliferatoractiv
receptor
well
extracellular
factor
vascular
nich
hypoxia
tumorassoci
macrophag
cancerassoci
fibroblast
cancerassoci
mesenchym
stem
cell
extracellular
matrix
exosom
shown
import
regul
csc
molecul
vaccin
antibodi
cart
chimer
antigen
receptor
cell
cell
develop
specif
target
csc
factor
alreadi
undergo
clinic
trial
review
summar
character
identif
csc
depict
major
factor
pathway
regul
csc
develop
discuss
potenti
target
therapi
csc
signal
transduct
target
therapi
http
doi
cancer
chronolog
diseas
serious
threaten
human
life
mani
strategi
develop
cancer
treatment
includ
surgeri
radiotherapi
chemotherapi
target
therapi
treatment
incid
rate
cancer
stabl
women
declin
slightli
men
past
decad
cancer
death
rate
also
declin
howev
tradit
cancer
treatment
method
effect
malign
tumor
main
reason
failur
cancer
treatment
metastasi
recurr
heterogen
resist
chemotherapi
radiotherapi
avoid
immunolog
surveil
failur
could
explain
characterist
cancer
stem
cell
csc
csc
caus
cancer
relaps
metastasi
multidrug
resist
radiat
resist
abil
arrest
phase
give
rise
new
tumor
therefor
csc
could
consid
promis
target
cancer
treatment
csc
first
identifi
leukemia
isol
via
surfac
marker
express
csc
express
differ
surfac
marker
nestin
subsequ
found
mani
nonsolid
solid
tumor
cell
also
form
bulk
tumor
csc
gener
tumor
via
selfrenew
differenti
multipl
cellular
subtyp
activ
csc
control
mani
intracellular
extracellular
factor
factor
use
drug
target
cancer
treatment
understand
natur
csc
summar
characterist
method
identif
isol
regul
current
research
target
csc
cancer
therapi
basic
research
clinic
studi
deepen
tumor
biolog
research
clinic
diagnosi
cancer
treatment
significantli
improv
recent
year
howev
high
recurr
rate
high
mortal
rate
still
unresolv
close
relat
biolog
characterist
csc
understand
csc
characterist
research
tumor
biolog
enter
new
era
therefor
understand
biolog
properti
csc
great
signific
diagnosi
treatment
tumor
csc
strong
selfrenew
abil
direct
caus
tumorigenesi
csc
symmetr
divid
two
csc
one
csc
one
daughter
cell
csc
expand
symmetr
split
manner
excess
increas
cell
growth
ultim
lead
tumor
format
csc
isol
origin
tumor
tissu
transplant
sever
combin
immunodefici
diseas
scid
mice
form
new
tumor
csc
normal
stem
cell
also
share
regulatori
signal
pathway
sonic
hedgehog
hh
notch
pathway
involv
selfrenew
process
addit
signal
molecul
pten
polycomb
famili
also
play
import
role
regul
csc
growth
regul
csc
selfrenew
key
link
understand
tumorigenesi
studi
provid
clear
target
cancer
treatment
addit
selfrenew
abil
csc
also
abil
differenti
differ
cell
type
bonnet
dick
demonstr
leukemia
stem
cell
lsc
abil
differenti
prolifer
scid
mice
brain
csc
isol
patient
posit
marker
nestin
marker
normal
neuron
stem
cell
cell
lack
surfac
marker
differenti
gener
variou
signal
pathway
regul
selfrenew
differenti
normal
stem
cell
promot
prolifer
differenti
rel
balanc
manner
regulatori
balanc
destroy
uncontrol
csc
ultim
lead
tumorigenesi
csc
also
transdifferenti
multilineag
cell
regul
tumorigenesi
bussolati
et
al
found
renal
csc
differenti
vascular
endotheli
cell
ec
bulk
tumor
form
scid
mice
inject
human
renal
csc
addit
csc
differenti
vascular
ec
promot
angiogenesi
found
varieti
cancer
glioblastoma
liver
cancer
metastasi
refer
process
cancer
cell
travel
primari
site
lymphat
vessel
blood
vessel
bodi
caviti
sinc
stromal
cell
granulocyt
macrophag
secret
signal
molecul
tumor
microenviron
tme
cell
stimul
epithelialmesenchym
transform
emt
promot
invas
tumor
cell
induc
differenti
human
mammari
epitheli
cell
form
mammari
gland
activ
rasmapk
mitogenactiv
protein
kinas
signal
pathway
transform
nontumorigen
breast
cancer
cell
tumorigen
breast
cancer
cell
studi
show
csc
close
relat
emt
emt
like
basi
tumor
invas
metastasi
addit
pancreat
cancer
cell
hi
prostat
cancer
cell
also
tumorigen
therefor
studi
indic
csc
play
crucial
role
tumor
metastasi
develop
furthermor
understand
mechan
csc
drug
resist
vital
cancer
treatment
prevent
recurr
csc
effici
express
atpbind
cassett
abc
transport
includ
multidrug
resist
protein
protein
protect
leukemia
solid
tumor
cell
drug
damag
induc
drug
resist
accord
previou
studi
aldehyd
dehydrogenas
aldh
marker
mani
csc
elimin
oxid
stress
enhanc
resist
chemotherapeut
drug
oxazolidin
taxan
platinum
drug
aldh
also
remov
free
radic
induc
radiat
stimul
resist
radiat
induc
dna
damag
apoptosi
chemotherapi
radiotherapi
commonli
use
cancer
treatment
howev
csc
effect
protect
cancer
cell
apoptosi
activ
dna
repair
abil
current
believ
csc
key
seed
tumor
initi
develop
metastasi
recurr
csc
evolv
highli
heterogen
breast
csc
differ
express
pattern
surfac
biomark
sp
aldh
melanoma
stem
cell
form
tumor
scid
mice
heterogen
csc
also
found
cancer
includ
glioblastoma
prostat
cancer
lung
cancer
heterogen
csc
complex
effect
biomark
need
identifi
csc
distinguish
heterogen
csc
known
proport
csc
tumor
tissu
low
gener
account
total
tumor
mass
addit
csc
normal
stem
cell
also
share
similar
transcript
factor
signal
pathway
therefor
challeng
isol
identifi
csc
howev
increas
number
techniqu
mean
emerg
csc
identifi
differ
biomark
human
cancer
tabl
csc
separ
combin
specif
biomark
mostli
locat
cell
surfac
primari
separ
techniqu
fluorescenceactiv
cell
sort
fac
magneticactiv
cell
sort
mac
sinc
dick
je
first
screen
csc
leukemia
use
fac
technolog
fac
becom
wide
use
techniqu
cell
separ
perform
multibiomark
sort
one
time
high
puriti
strong
specif
mac
mac
techniqu
mac
separ
rel
simpl
techniqu
cumbersom
therefor
method
requir
high
activ
csc
two
method
effect
separ
csc
larg
number
cell
addit
way
separ
csc
tumor
dr
goodel
observ
ad
hoechst
cultur
bone
marrow
cell
cell
accumul
dye
claim
cell
side
popul
sp
cell
therefor
sp
cell
separ
fluoresc
screen
outflow
hoechst
recent
sp
cell
identifi
variou
normal
tissu
tumor
cell
sp
cell
high
homolog
selfrenew
multidirect
differenti
potenti
report
shown
highli
express
sp
cell
highli
relat
drug
resist
csc
use
phenotyp
marker
csc
includ
ovarian
cancer
aml
breast
cancer
lung
cancer
nasopharyng
carcinoma
hepatocellular
carcinoma
hcc
montanaro
et
al
explor
optim
concentr
hoechst
reduc
toxic
effect
sp
sort
method
univers
applic
separ
identif
csc
especi
csc
unknown
cell
surfac
marker
effect
method
csc
research
colonyform
abil
csc
also
use
separ
identif
digest
tumor
tissu
singl
cell
lowdens
cell
cultur
conduct
serumfre
medium
contain
epitheli
growth
factor
egf
basic
fibroblast
growth
factor
fgf
condit
singl
csc
form
cell
coloni
sphere
taylor
et
al
success
isol
csc
varieti
neurolog
tumor
use
coloni
format
assay
howev
cell
purif
rate
low
csc
specif
poor
assay
vivo
limit
dilut
assay
lda
use
assess
csc
activ
lowdens
transplant
immunedefici
mice
limit
dilut
method
csc
identifi
elda
softwar
analysi
method
affect
cell
densiti
microenviron
mice
tradit
chemotherapeut
drug
mainli
affect
cancer
cell
csc
mostli
arrest
phase
rel
static
thu
evad
kill
effect
chemotherapeut
drug
henc
drugresist
characterist
csc
use
isol
identifi
csc
previou
studi
shown
radiotherapi
combin
hypox
cultur
also
use
enrich
csc
addit
separ
csc
also
accomplish
physic
method
hepatoma
stem
cell
isol
rat
liver
cancer
tissu
percol
densiti
gradient
centrifug
cell
fraction
high
nucleartocytoplasm
ratio
obtain
recent
rahimi
et
al
use
host
gene
promot
overexpress
neomycin
cancer
cell
select
collect
neomycinresist
csc
csc
origin
least
four
cell
type
includ
normal
stem
cell
direct
group
progenitor
cell
matur
cell
fusion
stem
cell
mutant
cell
therefor
transform
csc
normal
cell
requir
multipl
gene
mutat
epigenet
chang
uncontrol
signal
pathway
continu
regul
microenviron
current
believ
mani
similar
csc
embryon
stem
es
cell
especi
regard
abil
grow
indefinit
selfrenew
signal
pathway
transcript
factor
addit
csc
exist
support
microenviron
vital
surviv
moreov
complex
interact
csc
microenviron
regul
csc
growth
section
discuss
effect
transcript
factor
signal
pathway
microenviron
csc
surviv
apoptosi
metastasi
gener
stem
cell
least
two
common
characterist
abil
selfrenew
potenti
differenti
one
special
cell
type
somat
cell
reprogram
becom
induc
pluripot
stem
cell
transient
ectop
overexpress
transcript
factor
nanog
myc
addit
similar
csc
es
cell
reason
embryon
transcript
factor
reexpress
reactiv
csc
therefor
transcript
factor
play
import
role
regul
csc
growth
homeodomain
transcript
factor
pitoctunc
famili
recogn
one
import
transcript
factor
recent
emerg
master
regul
control
pluripot
selfrenew
mainten
stem
cell
studi
report
highli
express
csc
high
express
posit
correl
glioma
grade
promot
selfrenew
chemoresist
tumorigen
hcc
stem
cell
high
express
also
observ
breast
csclike
cell
cisplatin
etoposid
adriamycin
paclitaxel
upregul
express
lung
cancer
cell
cell
resist
drug
treatment
cell
data
also
show
express
associ
poor
clinic
outcom
hormon
receptorposit
breast
cancer
knockdown
also
reduc
stem
germ
cell
tumor
henc
studi
proven
pluripot
factor
csc
belong
famili
highmobl
group
transcript
factor
play
signific
function
earli
develop
mainten
undifferenti
esc
also
one
key
transcript
factor
csc
rodriguezpinilla
et
al
found
increas
express
basallik
breast
cancer
may
help
character
poorli
differentiatedstem
cell
phenotyp
hagerstrand
et
al
also
found
high
level
induc
xenograft
glioma
studi
show
knockout
inhibit
glioblastoma
cell
prolifer
tumorigen
suggest
basi
maintain
selfrenew
abil
tumoriniti
cell
tic
also
studi
suggest
promot
selfrenew
tumorigenesi
inhibit
differenti
csc
nanog
differenti
homeobox
hox
domain
protein
first
discov
esc
typic
selfrenew
multipot
transcript
regulatori
function
although
nanog
silenc
normal
somat
cell
abnorm
express
report
human
cancer
breast
cancer
cervic
cancer
brain
cancer
colon
cancer
head
neck
cancer
lung
cancer
gastric
cancer
compar
level
benign
tissu
nanog
messeng
rna
mrna
elev
malign
tumor
number
patient
colorect
cancer
n
high
nanog
protein
associ
lymph
node
posit
duke
grade
similarli
overexpress
nanog
colorect
csc
promot
coloni
format
tumorigen
vivo
addit
gastric
cancer
patient
high
nanog
level
lower
surviv
rate
express
level
nanog
increas
hcc
cell
line
primari
tumor
associ
advanc
diseas
tumor
node
metastasi
tnm
stage
iii
iv
studi
prostat
cell
line
xenograft
primari
tumor
found
nanog
short
hairpin
rna
inhibit
format
primari
prostat
cancer
cell
pca
sphere
clonal
growth
tumorigenesi
case
pancreat
cancer
tissu
microarray
analysi
kaplanmei
analysi
show
high
express
nanog
predict
wors
prognosi
neg
correl
patient
surviv
studi
indic
nanog
play
import
role
regul
selfrenew
prolifer
csc
express
mani
tissu
play
import
role
mani
differ
physiolog
process
bifunct
transcript
factor
activ
inhibit
transcript
accord
differ
target
gene
util
differ
mechan
play
oncogen
anticanc
role
depend
type
cancer
involv
exampl
anticanc
factor
intestin
epithelium
gastric
epithelium
express
downregul
hypermethyl
loss
heterozygos
colorect
csc
gastric
csc
downregul
also
found
cancer
nonsmallcel
lung
carcinoma
liver
cancer
leukemia
anaplast
meningioma
bladder
cancer
esophag
cancer
although
data
clearli
demonstr
play
anticanc
role
cancer
may
also
oncogen
demonstr
first
time
nearli
decad
overexpress
transform
rat
renal
epitheli
cell
induc
tumorigenesi
laryng
scc
addit
deplet
inhibit
melanoma
xenograft
growth
vivo
high
express
oncogen
human
breast
csc
correl
aggress
phenotyp
canin
mammari
tumor
studi
suggest
differ
function
differ
csc
myc
three
famili
member
cmyc
nmyc
lmyc
encod
protooncogen
famili
essenti
transcript
factor
dnabind
protein
basic
helixloophelix
bhlh
superfamili
myc
regul
larg
number
proteincod
noncod
gene
coordin
variou
biolog
process
stem
cell
cell
metabol
selfrenew
differenti
growth
although
myc
gene
one
commonli
activ
oncogen
involv
pathogenesi
human
cancer
overexpress
myc
alon
surprisingli
unabl
induc
transform
normal
cell
tumor
cell
overexpress
myc
normal
human
cell
may
ineffect
highli
destruct
result
stagnat
prolifer
age
apoptosi
myc
usual
deregul
human
cancer
play
import
role
maintain
number
invas
csc
also
one
effect
oncogen
detect
cell
transform
phenotyp
vitro
vivo
previou
studi
shown
delet
tumor
suppressor
gene
myc
synerg
induc
hepatocyt
prolifer
tumorigenesi
addit
delet
overexpress
loss
also
assist
myc
regul
surviv
prolifer
csc
express
three
member
myc
famili
differ
differ
tumor
cmyc
leukemia
tongu
scc
stem
cell
nmyc
smallcel
lung
cancer
prostat
cancer
neuroblastoma
medulloblastoma
lmyc
express
hematopoiet
malign
addit
inactiv
myc
result
hcc
stem
cell
differenti
hepatocyt
biliari
duct
cell
form
bile
duct
structur
might
associ
loss
tumor
marker
increas
express
cytokeratin
hepatocyt
marker
carcinoembryon
antigen
liver
stem
cell
marker
cytokeratin
studi
also
shown
myc
highli
express
glioblastoma
multiform
stem
cell
induc
cell
prolifer
invas
inhibit
apoptosi
increas
copi
number
myc
gene
human
mous
prostat
csc
also
found
studi
indic
myc
induc
tumorigenesi
help
factor
major
signal
pathway
csc
mani
signal
pathway
contribut
surviv
prolifer
selfrenew
differenti
properti
normal
stem
cell
abnorm
activ
repress
tumorigenesi
csc
mani
endogen
exogen
gene
microrna
regul
complex
pathway
signal
pathway
also
induc
downstream
gene
express
cytokin
growth
factor
apoptosi
gene
antiapoptot
gene
prolifer
gene
metastasi
gene
csc
signal
pathway
singl
regul
interwoven
network
signal
mediat
regul
csc
growth
therefor
section
describ
signal
pathway
regul
csc
growth
wnt
signal
pathway
csc
wnt
includ
larg
protein
ligand
affect
divers
process
gener
cell
polar
cell
fate
wnt
pathway
highli
complex
evolutionarili
conserv
includ
wnt
ligand
receptor
wnt
signal
pathway
divid
canon
wnt
signal
receptor
complex
lead
derepress
noncanon
wnt
signal
fzd
receptor
andor
coreceptor
activ
pcp
rtk
ca
signal
cascad
canon
wnt
signal
absenc
wnt
ligand
inact
wnt
signal
state
fig
left
phosphoryl
glycogen
synthas
kinas
lead
degrad
via
ubiquitin
inhibit
transloc
cytoplasm
nucleu
contrast
presenc
wnt
ligand
eg
ligand
combin
fzd
receptor
lrp
coreceptor
activ
wnt
signal
fig
right
lrp
receptor
phosphoryl
releas
axin
complex
enter
nucleu
addit
combin
leftcf
enhanc
recruit
histonemodifi
coactiv
pygo
activ
transcript
noncanon
wnt
signal
involv
wntpcp
signal
dvl
activ
bind
wnt
ligand
rorfrizzl
receptor
dvl
inhibit
bind
small
gtpase
rho
cytoplasm
protein
small
gtpase
rho
togeth
trigger
rock
rho
kinas
jnk
cjun
ntermin
kinas
result
cytoskelet
rearrang
andor
transcript
respons
wntca
signal
activ
g
proteintrigg
phospholipas
c
activ
result
intracellular
calcium
flux
downstream
calciumdepend
cytoskelet
andor
transcript
respons
aberr
wnt
signal
found
mani
cancer
invas
ductal
breast
carcinoma
colorect
cancer
papillari
thyroid
cancer
esophag
cancer
colorect
cancer
activ
wnt
signal
differ
differ
tumor
wnt
activ
caus
mutat
wnt
compon
axin
mutat
gastrointestin
cancer
apc
mutat
colorect
cancer
mutat
gastric
cancer
liver
cancer
gene
critic
regul
therefor
mani
research
expect
occurr
mutat
mutat
correl
cancer
occurr
addit
gene
pyruv
kinas
isozym
breast
cancer
telomeras
revers
transcriptas
tert
prostat
cancer
microrna
colorect
cancer
nonsmallcel
lung
cancer
inhibit
activ
apc
axin
promot
accumul
cytoplasm
stem
cell
signal
pathway
transcript
circuit
relat
alter
reactiv
signal
pathway
tumor
dormanc
lag
phenomenon
tumor
growth
dormanc
may
occur
primari
tumor
format
diffus
constitu
tumor
cell
howev
primari
tumor
dormanc
metastat
dormanc
seem
differ
process
case
cell
tme
produc
cytokin
wnt
protein
secret
inhibitor
bone
morphogenet
protein
bmp
delta
activ
signal
pathway
maintain
selfrenew
abil
csc
activ
wnt
induc
transform
dormant
csc
activ
csc
promot
cell
cycl
progress
increas
express
downstream
cyclin
myc
myc
also
promot
express
polycomb
repressor
complex
compon
induc
combin
cyclin
e
extracellular
matrix
ecm
protein
tenascin
c
often
exist
gap
stem
cell
support
cell
cycl
breast
cancer
cell
increas
wnt
signal
addit
aberr
wnt
signal
also
observ
selfrenew
csc
fig
mani
report
proven
numer
protooncogen
stimul
process
wnt
signal
pathway
catalyz
last
step
glycolysi
play
essenti
role
prolifer
breast
csc
associ
increas
level
region
enhanc
zest
homolog
key
compon
polycomb
complex
promot
selfrenew
csc
activ
moreov
tert
rnadepend
dna
polymeras
act
cofactor
form
complex
activ
wnt
downstream
target
fig
pathway
cancer
stem
cell
canon
pathway
regul
pluripot
csc
determin
differenti
fate
csc
absenc
wnt
signal
bound
axin
complex
contain
apc
phosphoryl
lead
ubiquitin
proteasom
degrad
pathway
howev
complex
tazyap
long
noncod
rna
protein
regul
pathway
presenc
wnt
signal
bind
fzd
inhibit
activ
axin
complex
phosphoryl
make
enter
nucleu
bind
teftcf
form
complex
recruit
cofactor
initi
downstream
gene
express
protein
dickkopfrel
protein
gecg
myc
tert
microrna
long
noncod
rna
regul
activ
pathway
csc
prostat
csc
capillari
morphogenesi
gene
increas
express
nuclear
regul
selfrenew
tumorigen
gastric
csc
locat
downstream
wnt
pathway
similar
effect
addit
long
noncod
rna
microrna
also
promot
selfrenew
csc
wnt
signal
pathway
recruit
swisnf
complex
regul
express
promot
liver
csc
associ
methyltransferas
suppress
ubiquitin
promot
stabil
interact
maintain
stabil
activ
signal
suppress
express
axin
csc
downregul
lung
csc
upregul
express
gastric
csc
addit
still
mani
gene
microrna
noncod
rna
csc
selfrenew
wnt
signal
pathway
wnt
signal
also
play
import
role
dedifferenti
csc
member
hox
famili
induc
differenti
colorect
csc
howev
wnt
indirectli
suppress
indirectli
via
myc
import
direct
target
intestin
integr
membran
glycoprotein
myelin
peripher
nervou
system
induc
differenti
gastric
csc
mrna
level
declin
activ
pathway
moreov
compon
heatshock
protein
chaperon
famili
inhibit
differenti
colorect
carcinoma
stem
cell
modul
ubiquitin
phosphoryl
member
g
proteincoupl
receptor
gpcr
famili
protein
locat
downstream
wnt
signal
pathway
restrain
differenti
esophag
scc
stem
cell
wnt
signal
also
play
import
role
regul
csc
apoptosi
dickkopfrel
protein
induc
arrest
cell
apoptosi
suppress
activ
breast
csc
homolog
dapper
locat
chromosom
region
promot
apoptosi
breast
csc
antagon
signal
pathway
proapoptot
tumor
suppressor
reduc
level
activ
induc
apoptosi
colorect
csc
increas
apoptosi
degrad
lung
csc
smallmolecul
inhibitor
antagon
bind
tcf
nucleu
induc
apoptosi
liver
csc
addit
temozolomid
combin
significantli
induc
apoptosi
target
signal
pathway
glioma
stem
cell
signal
implic
cscmediat
metastasi
cytomembran
promot
bone
metastasi
prostat
csc
leucinerich
repeat
contain
togeth
famili
member
bind
rspondin
lead
potenti
activ
wnt
signal
breast
csc
increas
level
mrna
human
pancreat
csc
lung
csc
colon
csc
promot
migrat
metastasi
activ
cytoplasm
tazyap
interact
directli
restrict
degrad
antagon
tazyap
accumul
transloc
cytoplasm
nucleu
moreov
inhibit
migrat
invas
colorect
csc
inhibit
wnt
aktrhoa
signal
wnt
signal
decreas
express
promot
csc
metastasi
data
suggest
amplifi
wnt
signal
import
selfrenew
dedifferenti
apoptosi
inhibit
metastasi
csc
notch
signal
pathway
csc
notch
signal
pathway
consist
notch
receptor
notch
ligand
dsl
protein
csl
suppressor
hairless
lag
dnabind
protein
effector
notch
regulatori
molecul
studi
discov
notch
gene
mutant
drosophila
mammal
four
notch
receptor
five
notch
ligand
deltalik
jag
jag
notch
dsl
ligand
transmembran
protein
mediat
commun
neighbor
cell
physiolog
condit
ligand
bind
notch
receptor
express
neighbor
cell
juxtacrin
manner
therebi
trigger
proteolyt
cleavag
intracellular
domain
icd
notch
transloc
nucleu
bind
transcript
factor
csl
form
nicdcsl
transcript
activ
complex
activ
target
gene
bhlh
transcript
inhibitor
famili
he
hey
herp
notch
pathway
regul
cancer
cell
mani
tumor
glioblastoma
leukemia
breast
pancrea
colon
lung
among
other
differ
tumor
tumor
subtyp
express
differ
notch
ligand
receptor
therefor
notch
known
function
oncogen
suppress
gene
oncogen
notch
overexpress
gastric
cancer
breast
cancer
colon
cancer
pancreat
cancer
contrast
notch
express
downregul
prostat
cancer
skin
cancer
nonsmallcel
lung
cancer
liver
cancer
breast
cancer
whether
notch
act
oncogen
tumor
suppressor
gene
determin
microenviron
moreov
posttransl
modif
notch
receptor
chang
affin
ligand
intracellular
halfliv
mani
studi
notch
pathway
csc
shown
activ
notch
promot
cell
surviv
selfrenew
metastasi
inhibit
apoptosi
aberr
notch
signal
promot
selfrenew
metastasi
breast
hcc
stem
cell
howev
downregul
similarli
abund
deltalik
ligand
also
promot
tumor
angiogenesi
metastasi
gastric
csc
deltalik
activ
signal
requir
assist
actinrel
protein
complex
maintain
stem
cell
phenotyp
gliomainiti
cell
addit
intracellular
gene
also
regul
notch
signal
pathway
exampl
nonglycosyl
membraneassoci
protein
locat
plasma
membran
golgi
apparatu
interact
numb
pdzbind
domain
activ
notch
pathway
cervic
csc
induc
nitric
oxid
synthas
promot
selfrenew
capac
liver
csc
tace
activ
regul
signal
moreov
tumor
necrosi
enhanc
csclike
phenotyp
activ
signal
oral
scc
cell
overexpress
decreas
express
jag
colorect
csc
addit
also
increas
jag
breast
csc
regul
cell
migrat
invas
key
regul
breast
cancer
cell
differenti
howev
local
conserv
intron
enhanc
region
within
notch
ligand
jag
gene
maintain
stem
breast
csc
similarli
increas
also
promot
cell
prolifer
invas
oral
scc
increas
hypoxiahypoxiainduc
factor
hif
induc
migrat
invas
wellknown
phenomenon
report
numer
csc
induc
migrat
invas
ovarian
csc
absenc
hypoxia
hypoxiainduc
jag
activ
enhanc
cell
invas
breast
csc
lung
csc
moreov
regul
selfrenew
mainten
glioblastoma
stem
cell
addit
increas
decreas
notch
signal
promot
pancreat
csc
becom
asymmetr
directli
target
jag
inhibit
osteosarcoma
csc
prolifer
studi
indic
notch
play
import
role
regul
selfrenew
growth
metastasi
csc
target
cancer
stem
cell
pathway
cancer
therapi
yang
et
al
hh
signal
pathway
csc
hh
signal
pathway
consist
ligand
receptor
hh
signal
network
complex
includ
extracellular
hh
ligand
transmembran
protein
receptor
ptch
transmembran
protein
smo
intermedi
transduct
molecul
downstream
molecul
gli
compon
hh
signal
pathway
play
differ
role
membran
protein
smo
play
posit
regulatori
role
transmembran
protein
ptch
play
neg
regulatori
role
ptch
two
subtyp
homolog
two
subtyp
gli
effector
protein
three
subtyp
vertebr
effector
protein
differ
function
strongli
activ
transcript
inhibit
transcript
dual
function
activ
inhibit
transcript
mainli
function
transcript
activ
numer
studi
confirm
hh
signal
involv
embryon
develop
format
nervou
system
skeleton
limb
lung
heart
gut
extracellular
signal
pathway
presenc
ligand
signal
hh
ligand
bind
ptch
receptor
target
cell
membran
initi
seri
intracellular
signal
transduct
process
ligand
signal
transmembran
receptor
ptch
target
cell
membran
bind
smo
inhibit
smo
activ
prevent
signal
hh
ligand
present
bind
ptch
chang
spatial
conform
ptch
remov
inhibit
smo
activ
transcript
factor
gli
induc
enter
cell
nucleu
gli
regul
cell
growth
prolifer
differenti
studi
confirm
abnorm
activ
hh
signal
pathway
found
human
cancer
breast
cancer
lung
cancer
bladder
cancer
pancreat
cancer
chondrosarcoma
rhabdomyosarcoma
neuroblastoma
medulloblastoma
gastric
cancer
howev
activ
hh
signal
differ
differ
tumor
gorlin
syndrom
basal
cell
nevu
syndrom
autosom
domin
condit
associ
germlin
loss
gene
condit
common
basal
cell
carcinoma
rhabdomyosarcoma
medulloblastoma
hh
pathway
compon
also
mutat
human
cancer
mutat
pancreat
adenocarcinoma
gene
amplif
glioblastoma
sufu
suppressor
fuse
mutat
medulloblastoma
addit
gene
also
regul
hh
signal
pathway
speckletyp
poz
protein
ubiquitin
ligas
adaptor
inhibit
hh
signal
acceler
degrad
gastric
cancer
hh
signal
play
distinct
function
differ
type
cancer
tumor
develop
hh
signal
three
major
role
drive
tumor
develop
promot
tumor
growth
regul
residu
cancer
cell
therapi
base
function
aberr
hh
pathway
play
causal
role
csc
fig
express
level
hh
signal
fig
hedgehog
signal
pathway
cancer
stem
cell
hedgehog
pathway
play
key
role
stem
mainten
selfrenew
regener
csc
secret
hh
protein
act
concentrationand
timedepend
manner
initi
seri
cell
respons
cell
surviv
prolifer
differenti
receiv
shh
signal
transmembran
protein
receptor
ptch
reliev
inhibit
transmembran
protein
smo
induc
detach
sufu
enter
nucleu
regul
downstream
gene
transcript
activ
hh
pathway
protein
fbox
leucinerich
repeat
protein
ppkci
histon
deacetylas
vasohibin
forkhead
box
microrna
long
noncod
rna
involv
hedgehog
pathway
affect
csc
growth
compon
rel
high
csc
exampl
hh
signal
promot
mainten
prolifer
selfrenew
tumorigen
lung
adenocarcinoma
stem
cell
glioma
stem
cell
smo
gli
ptch
promot
cell
prolifer
selfrenew
migrat
invas
express
regul
histon
deacetylas
activ
glidepend
transcript
stabil
protein
glioma
stem
cell
protein
kinas
enhanc
express
transcript
activ
lung
csc
nuclear
serthr
phosphatas
also
enhanc
function
increas
transcript
activ
protein
stabil
nuclear
local
breast
csc
medulloblastoma
fbox
leucinerich
repeat
protein
mediat
releas
sufu
proper
hh
signal
transduct
medulloblastoma
stem
cell
moreov
retino
acid
receptor
upregul
express
smo
multipl
myeloma
stem
cell
prkci
regul
tongu
scc
similar
function
maintain
stemlik
phenotyp
lung
scc
cell
activ
hh
signal
nonsmallcel
lung
csc
selfrenew
mainten
stem
bladder
csc
glycotransferas
glycosyl
significantli
activ
sonic
hh
signal
upregul
furthermor
master
regul
normal
epitheli
stem
cell
mainten
regul
express
shh
directli
bind
gene
regulatori
region
eventu
contribut
activ
hh
signal
mammari
csc
ntermin
domain
forkhead
box
bind
directli
intern
region
amino
acid
aa
enhanc
transcript
activ
determin
stem
cell
phenotyp
breast
csc
recruit
deubiquitin
enzym
interact
inhibit
degrad
complex
addit
long
noncod
microrna
also
activ
hh
signal
exampl
promot
selfrenew
liver
csc
recruit
nurd
complex
onto
promot
gene
suppress
express
addit
tme
crucial
surviv
csc
consequ
breast
csc
secret
shh
upregul
cancerassoci
fibroblast
caf
subsequ
caf
secret
factor
promot
expans
selfrenew
breast
csc
hh
signal
also
promot
selfrenew
metastasi
csc
upregul
express
relat
downstream
marker
csc
cmyc
nanog
plateletderiv
factor
snail
jag
cmet
protooncogen
suppressor
gene
also
directli
indirectli
regul
hh
signal
prolifer
migrat
csc
signal
peptid
cub
egflik
domaincontain
protein
member
scube
famili
protein
inhibit
cell
prolifer
migrat
glioma
stem
cell
downregul
hh
signal
transcript
repressor
lymphoma
oncoprotein
directli
repress
sonic
hh
effector
medulloblastoma
stem
cell
transcript
factor
suppress
metastasi
stem
colorect
csc
promot
ubiquitin
intracellular
level
vasohibin
suppress
smo
express
pancreat
csc
stabli
increas
physic
interact
result
degrad
medulloblastoma
stem
cell
addit
microrna
also
target
hh
signal
compon
regul
csc
prolifer
exampl
significantli
decreas
smo
myeloma
stem
cell
directli
downregul
smo
medulloblastoma
stem
cell
downregul
smo
glioma
stem
cell
target
shh
lung
csc
data
demonstr
amplifi
hh
signal
import
selfrenew
growth
metastasi
csc
signal
pathway
csc
nuclear
rapidli
induc
transcript
factor
consist
five
differ
protein
relb
crel
main
physiolog
function
dimer
primari
mode
regul
occur
level
subcellular
local
activ
stage
transcript
factor
complex
must
transloc
cytoplasm
nucleu
activ
complex
regul
two
major
pathway
canon
signal
noncanon
signal
canon
activ
pathway
activ
occur
bind
ligand
bacteri
cell
compon
lipopolysaccharid
respect
receptor
tolllik
receptor
tnf
receptor
tnfr
receptor
antigen
receptor
stimul
receptor
lead
phosphoryl
activ
kinas
ikk
protein
subsequ
initi
phosphoryl
protein
altern
pathway
activ
term
noncanon
pathway
noncanon
pathway
receptor
origin
differ
class
receptor
activ
b
cell
activ
factor
lymphotoxin
pathway
lead
activ
induc
kinas
nik
phosphoryl
predominantli
activ
activ
latter
enzym
induc
phosphoryl
gener
pathway
play
import
role
regul
immun
inflammatori
respons
addit
pathway
involv
cellular
surviv
prolifer
differenti
process
tumor
develop
progress
produc
cytokin
growth
angiogen
factor
proteas
activ
signal
inflamm
recogn
hallmark
cancer
overactiv
signal
report
gastrointestin
genitourinari
gynecolog
head
neck
cancer
breast
tumor
multipl
myeloma
blood
cancer
howev
direct
alter
molecular
mutat
rare
report
human
cancer
base
recent
studi
regul
mani
gene
implic
cell
surviv
prolifer
metastasi
tumorigenesi
cancer
activ
also
directli
indirectli
enhanc
express
key
angiogenesi
factor
adhes
molecul
vascular
endotheli
growth
factor
vegf
growthregul
oncogen
pathway
essenti
connect
regul
inflamm
selfrenew
mainten
metastasi
csc
fig
cell
promot
selfrenew
metastasi
mainten
ovarian
csc
increas
express
rela
relb
mediat
nuclear
activ
dimer
high
level
nik
induc
activ
noncanon
pathway
regul
selfrenew
metastasi
breast
csc
moreov
stromal
cellderiv
also
effect
regul
transloc
cytoplasm
nucleu
inflammatori
mediat
prostaglandin
contribut
tumor
format
mainten
metastasi
activ
via
phosphoinositid
pathway
colorect
csc
chemokin
lowmolecularweight
proinflammatori
cytokin
import
mediat
cell
prolifer
metastasi
apoptosi
cc
chemokin
receptor
interact
ligand
chemokin
ligand
inhibit
apoptosi
induc
surviv
migrat
pancreat
cancer
stemlik
cell
increas
express
extracellular
signalregul
kinas
furthermor
b
cellspecif
moloney
murin
leukemia
viru
integr
site
also
enhanc
protein
gastric
csc
microrna
also
play
import
role
promot
prolifer
csc
promot
selfrenew
migrat
invas
breast
csc
inhibit
express
pten
induc
phosphoryl
akt
result
elev
addit
transcript
factor
also
inhibit
selfrenew
metastasi
csc
pathway
increas
express
identifi
differ
cancer
interact
inhibit
express
locat
downstream
affect
selfrenew
metastasi
colorect
csc
overexpress
block
activ
liver
csc
target
g
proteincoupl
receptor
kinaseinteract
protein
inhibit
erk
moreov
drug
inhibit
cell
prolifer
metastasi
csc
pathway
disulfiram
antialcohol
drug
inhibit
tumor
growth
induc
metastasi
via
pathway
breast
csc
sulforaphan
preferenti
inhibit
selfrenew
tripleneg
breast
csc
inhibit
subunit
transloc
downregul
transcript
activ
curcumin
regul
prolifer
metastasi
apoptosi
hcc
stem
cell
inhibit
pathway
data
demonstr
amplifi
signal
import
regul
apoptosi
prolifer
metastasi
csc
jakstat
signal
pathway
janu
kinasesign
transduc
activ
transcript
jakstat
signal
pathway
signal
transduct
pathway
stimul
cytokin
pathway
involv
mani
import
biolog
process
cell
prolifer
differenti
apoptosi
immun
regul
compar
complex
signal
pathway
signal
pathway
rel
simpl
three
compon
tyrosin
kinaserel
receptor
tyrosin
kinas
jak
transcript
factor
stat
mani
cytokin
growth
factor
transmit
signal
jakstat
signal
pathway
includ
granulocyt
macrophag
colonystimul
factor
growth
hormon
egf
pdgf
interferon
cytokin
growth
factor
correspond
receptor
cell
membran
common
characterist
receptor
receptor
kinas
activ
bind
site
tyrosin
kinas
jak
cell
bind
ligand
tyrosin
residu
variou
target
protein
phosphoryl
jak
activ
achiev
signal
transduct
extracellular
intracellular
space
jak
protein
famili
consist
four
member
jak
protein
seven
jak
homolog
jh
domain
structur
domain
kinas
domain
domain
pseudo
kinas
domain
receptor
bind
domain
stat
call
signal
transduc
activ
transcript
name
impli
stat
play
key
role
signal
transduct
transcript
activ
present
seven
member
stat
famili
identifi
structur
stat
protein
divid
follow
function
region
ntermin
conserv
sequenc
dnabind
region
domain
domain
ctermin
transcript
activ
region
gener
mani
cytokin
growth
factor
integr
tyrosin
kinaserel
receptor
receiv
signal
upstream
receptor
molecul
jak
quickli
recruit
activ
receptor
result
jak
activ
catalyz
tyrosin
phosphoryl
receptor
phosphoryl
tyrosin
receptor
molecul
signal
molecul
bind
site
stat
stat
bind
receptor
tyrosin
phosphoryl
stat
also
occur
form
dimer
enter
nucleu
activ
transcript
factor
stat
dimer
directli
affect
express
relat
gene
chang
prolifer
differenti
target
cell
constitut
activ
jak
stat
first
recogn
associ
malign
base
current
studi
mutat
abnorm
activ
prone
occur
mani
tumor
mutat
report
major
patient
myeloprolif
neoplasm
polycythemia
vera
myelofibrosi
thrombocythemia
disord
caus
overexpans
hematopoiet
precursor
often
clonal
result
leukemia
sever
line
evid
show
constitut
activ
absenc
stimul
ligand
occur
polycythemia
vera
moreov
studi
also
found
aberr
activ
stat
human
cancer
head
neck
cancer
endometri
cancer
breast
cancer
diffus
larg
b
cell
lymphoma
hcc
colorect
cancer
glioma
colon
cancer
furthermor
aberr
signal
found
pathogenesi
hematolog
solid
organ
malign
jakstat
pathway
evolutionarili
conserv
pathway
promot
surviv
selfrenew
hematopoiesi
neurogenesi
esc
pathway
also
activ
csc
persist
activ
significantli
promot
cell
surviv
mainten
stem
breast
csc
induc
cell
selfrenew
migrat
invas
nonsmallcel
lung
csc
activ
pathway
aldh
high
endometri
csc
furthermor
also
induc
convers
nonstem
cancer
cell
cancer
stemlik
cell
breast
cancer
activ
downstream
gene
also
activ
pathway
ovarian
csc
breast
colorect
csc
erythropoietin
activ
pathway
retinolbind
protein
activ
signal
receptor
colon
csc
enhanc
selfrenew
glioma
stemlik
cell
pathway
ajuba
scaffold
protein
particip
regul
cell
adhes
differenti
prolifer
migrat
promot
surviv
prolifer
colorect
csc
via
pathway
moreov
microrna
also
involv
activ
jakstat
signal
inhibit
neg
regulatori
factor
exampl
target
multipl
neg
regul
signal
pathway
ptpn
hcc
stem
cell
lead
constitut
activ
signal
target
glioma
stem
cell
downregul
express
induc
differenti
breast
csc
neg
regul
receptor
gene
express
lung
csc
addit
endogen
exogen
gene
inhibit
jakstat
signal
csc
von
hippellindau
suppress
tumorigen
selfrenew
abil
glioma
stem
cell
inhibit
although
studi
jak
csc
role
jakstat
signal
surviv
selfrenew
metastasi
csc
tgfsmad
signal
pathway
csc
signal
pathway
involv
mani
cellular
process
associ
organ
embryo
develop
includ
cell
prolifer
differenti
apoptosi
homeostasi
although
signal
pathway
regul
wide
rang
cellular
process
structur
rel
simpl
superfamili
ligand
bind
type
ii
receptor
recruit
type
receptor
phosphoryl
type
receptor
phosphoryl
receptorregul
smad
rsmad
bind
common
pathway
smad
cosmad
rsmadcosmad
complex
act
transcript
factor
accumul
nucleu
regul
express
target
gene
superfamili
ligand
includ
bmp
growth
differenti
factor
gdf
antimullerian
hormon
amh
activin
nodal
ligand
divid
two
group
bmpgdf
group
includ
activin
nodal
bmpgdf
group
includ
bmp
gdf
amh
ligand
base
smad
structur
function
smad
protein
divid
three
subfamili
receptoractiv
pathwayrestrict
smad
rsmad
cosmad
inhibitori
smad
ismad
includ
least
nine
smad
protein
rsmad
activ
type
receptor
form
transient
complex
receptor
two
type
smad
complex
arsmad
activ
activin
includ
brsmad
activ
bmp
includ
cosmad
includ
common
medium
variou
signal
transduct
process
ismad
includ
bind
activ
type
receptor
inhibit
regul
signal
transduct
famili
mani
studi
shown
activ
tgfsmad
signal
also
occur
human
cancer
secret
protein
inhibit
express
matrix
metallopeptidas
prevent
migrat
invas
prostat
cancer
cancer
upregul
gene
promot
cellular
transform
stem
mediat
nuclear
protein
signal
lung
cancer
tgfsmad
also
play
import
role
cell
prolifer
csc
cyclin
interact
activ
promot
cyclin
signal
regul
selfrenew
liver
csc
bind
receptor
upregul
signal
colorect
csc
upregul
induc
express
liver
csc
also
upregul
express
activ
mapk
signal
pathway
regul
glycolysi
glioma
stem
cell
furthermor
silenc
shca
express
also
induc
activ
breast
csc
moreov
inhibit
signal
pathway
hcc
stem
cell
newli
discov
target
gene
inhibitor
signal
inhibit
sphere
format
gastric
cancer
stemlik
cell
although
studi
tgfsmad
signal
pathway
csc
pathway
still
play
import
role
signal
pathway
csc
intracellular
phosphatidylinositol
kinas
consist
regulatori
subunit
catalyt
subunit
serinethreonin
serthr
kinas
phosphatidylinositol
kinas
activ
akt
serinethreonin
kinas
express
three
isoform
akt
protein
crucial
effector
directli
activ
respons
one
key
downstream
target
gene
akt
mammalian
target
rapamycin
mtor
complex
conserv
serinethreonin
kinas
form
two
distinct
multiprotein
complex
consist
mtor
raptor
two
neg
regul
deptor
phosphoryl
akt
serin
residu
lead
full
akt
activ
studi
show
mutat
pten
lead
inhibit
signal
glioblastoma
multiform
howev
delet
pten
neural
stem
cell
lead
neoplast
phenotyp
includ
cell
growth
promot
resist
cell
apoptosi
increas
migratori
invas
properti
vivo
inactiv
pten
activ
protein
kinas
b
found
solid
tumor
myeloprolif
neoplasia
leukemia
therefor
mtor
signal
pathway
vital
cell
prolifer
surviv
abnorm
activ
signal
found
cancer
nonsmallcel
lung
cancer
breast
cancer
prostat
cancer
burkitt
lymphoma
esophag
adenocarcinoma
colorect
cancer
although
extens
studi
cancer
studi
csc
signal
involv
ovarian
cancer
cell
prolifer
epithelialmesenchym
transit
signal
activ
also
enhanc
migrat
invas
prostat
pancreat
csc
downregul
pten
induc
activ
promot
surviv
mainten
stem
tumorigen
prostat
cancer
stemlik
cell
popul
activ
promot
cell
prolifer
migrat
invas
aldh
high
head
neck
squamou
csc
activ
mtor
promot
surviv
prolifer
breast
csc
nasopharyng
carcinoma
stem
cell
activ
also
increas
aldehyd
dehydrogenas
activ
colorect
csc
activ
upregul
express
hepat
csc
marker
epcam
epitheli
cellular
adhes
molecul
tumorigen
hepatocellular
csc
nucleotidebind
domain
leucinerich
repeat
nlr
belong
larg
famili
cytoplasm
sensor
also
known
associ
block
activ
kinas
akt
colorect
csc
addit
studi
shown
mtor
signal
pathway
close
relat
metabol
csc
exampl
low
folat
lf
stress
reprogram
metabol
signal
activ
mtor
signal
pathway
promot
metastasi
tumorigen
lung
cancer
stemlik
cell
howev
matcha
green
tea
mgt
inhibitor
mtor
inhibit
prolifer
breast
csc
target
mitochondri
metabol
glycolysi
multipl
cell
signal
pathway
link
aktmtor
pathway
csc
clearli
evid
ppar
signal
pathway
csc
peroxisom
proliferatoractiv
receptor
ppar
ligandactiv
nuclear
transcript
factor
first
clone
mous
liver
isseman
green
ppar
also
member
ligandactiv
transcript
factor
superfamili
nuclear
hormon
receptor
associ
retino
acid
steroid
thyroid
hormon
receptor
ppar
act
fat
sensor
regul
transcript
lipid
metabol
enzym
present
three
subtyp
encod
ppara
ppard
pparg
gene
respect
found
highli
express
hepatocyt
cardiac
myocyt
intestin
cell
renal
proxim
convolut
tubul
cell
abundantli
express
adipos
tissu
vascular
pariet
cell
monocytesmacrophag
ec
smooth
muscl
cell
myocardi
cell
express
almost
tissu
bodi
express
level
higher
recent
year
studi
found
ppar
close
relat
energi
lipid
sugar
metabol
cell
differenti
prolifer
apoptosi
inflammatori
reaction
ppar
exert
posit
neg
effect
regul
target
gene
express
bind
specif
peroxisom
locat
gene
regulatori
site
prolif
respons
element
natur
ligand
unsatur
fatti
acid
eicosan
acid
oxid
lowdens
lipoprotein
lowdens
lipoprotein
linol
acid
deriv
date
mani
report
role
ppar
cancer
cell
includ
prostat
cancer
breast
cancer
glioblastoma
neuroblastoma
pancreat
cancer
hepat
cancer
leukemia
bladder
cancer
thyroid
tumor
howev
function
ppar
csc
well
understood
except
report
tumor
suppressor
bind
activ
canon
respons
element
gene
breast
csc
reduc
high
mesenchym
stem
cell
msc
popul
inhibit
angiogenesi
activ
also
prevent
cell
spheroid
format
stem
celllik
properti
bladder
csc
induc
adipocyt
differenti
degrad
adipos
tissu
furthermor
express
restrain
yap
transcript
activ
induc
differenti
osteosarcoma
stem
cell
melanoma
cell
pathway
promot
polar
macrophag
prevent
cell
death
ovarian
csc
activ
promot
express
target
gene
pten
inhibit
mtor
signal
stunt
selfrenew
tumorigen
metastasi
cervic
csc
glioblastoma
stem
cell
liver
csc
howev
combin
express
inhibit
express
direct
methyl
promot
squamou
carcinoma
ppar
also
close
relat
metabol
csc
regul
metabol
reprogram
glioblastoma
stem
cell
lung
csc
mous
mammari
gland
cancer
transcript
coactiv
peroxisom
proliferatoractiv
receptor
gamma
coactiv
also
known
promot
csc
prolifer
invas
enhanc
oxid
phosphoryl
mitochondri
biogenesi
oxygen
consumpt
rate
breast
csc
addit
ampk
signal
pathway
adenosin
amp
activ
protein
kinas
ampdepend
protein
kinas
key
molecul
regul
bioenergi
metabol
core
studi
diabet
metabolicrel
diseas
ampk
express
variou
csc
relat
metabol
studi
shown
ampk
necessari
prostat
csc
maintain
glucos
balanc
metformin
antidiabet
drug
fight
cancer
target
ampk
signal
inhibit
cell
prolifer
metabol
colorect
csc
hcc
stem
cell
therefor
metformin
may
potenti
therapeut
regent
regul
energi
metabol
csc
studi
suggest
ppar
play
import
role
growth
csc
interact
signal
pathway
csc
mention
previous
complex
signal
transduct
pathway
linear
case
crosstalk
among
variou
pathway
occur
regul
csc
signal
work
togeth
promot
cell
surviv
prolifer
csc
member
tnf
receptor
superfamili
regul
manner
receptor
molecul
activ
signal
regul
develop
colorect
cancer
knockdown
result
inhibit
express
promot
nuclear
transloc
activ
addit
neg
regul
signal
studi
reveal
neg
effect
activ
liver
breast
colon
cancer
cell
leucin
zipper
tumor
suppressor
put
tumor
suppressor
activ
inhibit
activ
upregul
liver
colon
breast
cancer
cell
hh
signal
import
function
embryogenesi
stem
cell
mainten
tumorigenesi
signal
induc
express
crdbp
rnabind
protein
result
bind
stabil
mrna
lead
increas
express
transcript
activ
promot
surviv
prolifer
colorect
csc
howev
report
show
noncanon
hh
signal
posit
regul
wnt
signal
colon
csc
addit
crosstalk
pathway
promot
cell
growth
metastasi
mainten
csc
popul
downregul
enhanc
activ
promot
cell
popul
melanoma
csc
signal
induc
prolifer
metastasi
lung
csc
bind
activ
pathway
promot
prolifer
sustain
selfrenew
csc
hcc
silenc
decreas
express
inhibit
activ
wnt
notch
signal
liver
csc
activ
induc
lncrna
nkila
express
block
signal
inhibit
metastasi
breast
csc
also
directli
regul
express
breast
csc
limit
stem
cell
popul
furthermor
notch
pathway
togeth
regul
prolifer
metastasi
cutan
scc
stem
cell
signal
upregul
express
promot
surviv
prolifer
breast
csc
inhibit
increas
express
sonic
hh
pathway
cooper
inhibit
growth
pancreat
csc
increas
evid
show
crosstalk
regul
surviv
selfrenew
metastasi
csc
microenviron
csc
csc
interact
microenviron
adhes
molecul
paracrin
factor
microenviron
provid
suitabl
space
selfrenew
differenti
csc
protect
csc
genotox
increas
chemic
radiolog
toler
tme
mainli
consist
tumor
stroma
adjac
tissu
cell
microvessel
immun
cell
immun
molecul
csc
adapt
chang
tme
also
affect
tme
concurr
microenviron
also
promot
selfrenew
csc
induc
angiogenesi
recruit
immun
stromal
cell
promot
tumor
invas
metastasi
fig
vascular
nich
microenviron
csc
normal
vasculatur
compos
ec
basement
membran
pariet
cell
ec
basi
format
inner
surfac
blood
vessel
studi
report
glioblastoma
stem
cell
locat
around
blood
vessel
concept
cancer
microvascular
environ
first
propos
calabres
et
al
demonstr
direct
contact
ec
csc
occur
brain
tumor
csc
also
found
near
ec
cancer
papilloma
colorect
cancer
studi
also
show
glioma
stem
celllik
cell
differenti
cancer
cell
endotheli
progenitor
cell
final
matur
ec
csc
differenti
cancer
vascular
stem
cellsprogenitor
cell
directli
involv
angiogenesi
form
vasculogen
mimicri
directli
involv
microcircul
tumor
ec
also
promot
csclike
transform
cell
growth
shh
activ
hh
signal
moreov
secret
microvesicl
csc
promot
prolifer
human
umbil
vein
ec
form
tubelik
structur
vitro
vivo
mice
csc
plastic
also
demonstr
tumor
includ
neuroblastoma
renal
breast
ovarian
cancer
vascular
microenviron
maintain
initi
undifferenti
dormanc
stem
cell
support
selfrenew
invas
metastasi
csc
protect
csc
injuri
role
ec
signal
system
proven
maintain
surviv
selfrenew
head
neck
sc
stem
cell
pasquier
colleagu
show
treatment
ec
microparticl
breast
ovarian
cancer
model
increas
number
csc
promot
sphere
format
csc
interact
csc
blood
vessel
promot
selfrenew
csc
loop
csc
promot
cancer
angiogenesi
induc
secret
cytokin
vegf
hepatocyt
growth
factor
hgf
ec
vegf
receptor
play
key
role
vasculogen
mimicri
format
neovascular
tumor
initi
glioma
stemlik
cell
result
secret
vegf
stem
celllik
glioma
cell
higher
normal
cancer
cell
regul
prolifer
glioma
stem
cell
mtor
signal
pathway
subsequ
studi
shown
multipl
signal
integrin
notch
growth
factor
receptor
link
cell
surfac
maintain
stem
csc
hypoxia
microenviron
csc
hypoxia
key
compon
csc
format
mainten
hypox
microenviron
maintain
undifferenti
state
cancer
cell
enhanc
clone
rate
induc
express
specif
biomark
csc
hif
import
transcript
factor
regul
cellular
hypoxia
respons
inhibit
cell
apoptosi
heterodim
hif
compos
regul
prolifer
fate
csc
medulloblastoma
glioblastoma
multiform
activ
pathway
promot
csc
surviv
tumorigenesi
maintain
surviv
phenotyp
csc
also
regul
express
target
gene
ldha
thu
csc
adapt
new
method
cell
energi
metabol
avoid
apoptosi
caus
hypoxia
fig
microenviron
cancer
stem
cell
prolifer
selfrenew
differenti
metastasi
tumorigenesi
csc
csc
microenviron
csc
microenviron
mainli
compos
vascular
nich
hypoxia
tumorassoci
macrophag
cancerassoci
fibroblast
cancerassoci
mesenchym
stem
cell
extracellular
matrix
cell
respons
hypox
stress
matrix
induc
growth
factor
cytokin
vegf
regul
growth
csc
via
wnt
notch
signal
pathway
hif
also
regul
stem
csc
previou
studi
shown
csc
need
activ
maintain
selfsustain
hypox
condit
obtain
pluripot
upregul
gene
importantli
activ
cmyc
necessari
ensur
undifferenti
csc
wnt
notch
signal
pathway
regul
hypoxia
induc
emt
promot
stem
csc
increas
invas
resist
radiotherapi
chemotherapi
bind
notch
icd
enhanc
transcript
activ
hypox
microenviron
glioma
requir
notch
signal
pathway
ensur
selfrenew
undifferenti
statu
csc
tumorassoci
macrophag
csc
macrophag
import
compon
innat
immun
respons
group
cell
plastic
heterogen
infiltr
inflammatori
macrophag
origin
precursor
bone
marrow
mononuclear
cell
precursor
cell
infiltr
variou
tissu
blood
vessel
differenti
differ
subtyp
differ
microenviron
two
subtyp
macrophag
phenotyp
phenotyp
antiinflammatori
antitumor
effect
secret
proinflammatori
factor
chemokin
cxc
motif
ligand
macrophag
gener
consid
phenotyp
tumorassoci
macrophag
tam
immunosuppress
angiogenesispromot
effect
consid
tumorpromot
cell
type
macrophag
secret
cc
chemokin
ligand
low
express
high
express
cytokin
secret
macrophag
affect
prolifer
tumorigen
transform
apoptosi
csc
variou
signal
pathway
tam
close
relat
csc
stem
cell
transform
renal
epitheli
cell
cocultur
macrophag
induc
emt
transform
renal
cancer
cell
csc
express
nanog
anoth
studi
also
show
secret
macrophag
induc
transdifferenti
nonsmallcel
lung
cancer
cell
csc
express
jinushi
colleagu
also
report
tam
secret
maintain
selfrenew
abil
colon
breast
csc
knockout
significantli
inhibit
tumorigen
abil
scid
mice
tam
close
relat
glioma
stem
cell
growth
tam
mainli
distribut
near
glioma
stem
cell
accumul
pericapillari
hypox
area
glioma
stem
cell
recruit
maintain
macrophag
secret
potent
chemokin
membran
protein
ablat
tam
inhibit
tumorigenesi
glioma
stem
cell
recent
studi
shown
interact
tme
csc
regul
varieti
signal
pathway
macrophag
enhanc
invas
glioma
stemlik
cell
signal
pathway
tam
activ
signal
pathway
mous
breast
csc
secret
egf
promot
selfrenew
abil
csc
secret
tam
also
induc
emt
hepatocellular
cancer
cell
activ
pathway
cancerassoci
fibroblast
csc
caf
one
import
compon
tme
critic
tumor
develop
metastasi
origin
cell
stroma
entir
clear
current
studi
hypothes
five
possibl
sourc
transfer
fibroblast
host
stroma
emt
transdifferenti
perivascular
cell
emt
differenti
msc
deriv
bone
marrow
addit
caf
also
deriv
cell
type
smooth
muscl
cell
pericyt
adipocyt
immun
cell
clear
whether
differ
function
caf
differ
sourc
caf
affect
cancer
cell
growth
cellcel
interact
secret
variou
invas
molecul
cytokin
chemokin
inflammatori
mediat
caf
tme
play
indispens
role
gener
mainten
csc
caf
transform
cancer
cell
csc
studi
shown
caf
promot
emt
enhanc
express
prostat
csc
marker
secret
breast
cancer
caf
also
secret
activ
relat
pathway
increas
transcript
stimul
lung
cancer
cell
undergo
emt
csc
transform
caf
secret
matrix
metalloproteinas
induc
emt
promot
growth
stem
cellspecif
compon
tumor
paracrin
interact
caf
csc
critic
maintain
csc
nich
lung
csc
fibroblastderiv
regul
csc
gap
activ
thu
promot
progress
tumor
caf
adipocyt
also
secret
leptin
increas
globul
rate
breast
csc
vitro
caf
also
regul
prolifer
csc
signal
pathway
exampl
caf
increas
secret
activ
pathway
increas
express
stem
cell
marker
upregul
globul
rate
breast
cancer
caf
regul
tic
plastic
hcc
signal
caf
secret
high
level
activ
notch
signal
phosphoryl
thu
promot
stem
celllik
characterist
hcc
cell
similar
studi
shown
cafderiv
exon
enhanc
colon
stem
cell
resist
activ
wnt
signal
pathway
cancerassoci
msc
csc
msc
high
selfrenew
abil
multidirect
differenti
potenti
msc
also
specif
migrat
injur
site
tumor
tissu
easi
isol
expand
vitro
msc
consid
ideal
vector
gene
therapi
characterist
home
secret
cytokin
tumor
howev
tumorigen
characterist
msc
still
need
studi
msc
promot
tumor
develop
also
inhibit
cancer
cell
growth
bone
marrow
msc
promot
tumor
growth
promot
angiogenesi
metastasi
surviv
csc
msc
tme
conduc
prolifer
carcinogenesi
metastasi
breast
csc
ionic
purinerg
signal
transduct
msc
differenti
caf
caf
regul
csc
promot
occurr
metastasi
cancer
possibl
mechan
relat
spontan
fusion
cancer
cell
msc
fusion
msc
breast
cancer
ovarian
cancer
gastric
cancer
lung
cancer
cell
vitro
vivo
confirm
msc
regul
tme
secret
maintain
undifferenti
state
osteosarcoma
cell
stimul
secret
via
autocrin
signal
ultim
activ
signal
cancer
cell
paracrin
manner
transform
cancer
cell
csc
ecm
bone
mesenchym
stem
cell
activ
pathway
induc
csc
phenotyp
secret
varieti
cytokin
chemokin
interact
mdsc
csc
via
notch
signal
critic
progress
breast
cancer
extracellular
matrix
csc
ecm
insolubl
structur
compon
matrix
mesenchym
epitheli
vessel
ecm
includ
collagen
elastin
aminoglycan
proteoglycan
noncollagen
glycoprotein
present
increas
evid
show
ecm
integr
part
stem
cell
nich
regul
balanc
stem
cell
three
differ
biolog
state
static
selfrenew
differenti
experi
vitro
vivo
shown
ecm
receptor
use
aggreg
csc
induc
drug
resist
fibronectin
vimentin
collagen
proteoglycan
ecm
bind
cytokin
fgf
hgf
vgf
bmp
tme
regul
activ
hcc
increas
matrix
promot
cell
prolifer
chemotherapeut
resist
increas
express
cscrelat
marker
includ
ckit
nanog
hyaluron
acid
ecm
ligand
receptor
regul
acquisit
mainten
csc
stem
mutual
contact
ecm
also
bind
wnt
ligand
via
molecular
lead
expans
prolifer
mammari
epitheli
stem
cell
addit
tenascin
c
ecm
maintain
stabil
breast
csc
increas
activ
wnt
notch
signal
pathway
exosom
tme
csc
exosom
nanovesicl
secret
variou
type
live
cell
nm
diamet
wide
distribut
peripher
blood
saliva
urin
ascit
pleural
effus
breast
milk
bodi
fluid
exosom
contain
larg
number
function
protein
rna
microrna
dna
fragment
bioactiv
substanc
bioactiv
substanc
mediat
materi
transport
inform
exchang
cell
thu
affect
physiolog
function
cell
exosom
secret
cancer
cell
promot
angiogenesi
induc
differenti
tumorrel
fibroblast
particip
immun
regul
tme
regul
microenviron
metastasi
clinic
analysi
reveal
exosom
releas
higher
level
cancer
cell
recent
studi
shown
endocytosi
lipid
raft
msc
associ
increas
secret
exosom
exosom
signal
mediat
interact
csc
normal
stem
cell
therebi
regul
oncogenesi
tumor
develop
exosom
also
regul
csc
growth
target
specif
signal
pathway
wnt
notch
hippo
hh
extracellular
vesicl
releas
glioblastoma
stem
cell
promot
neurospher
format
endotheli
tube
format
invas
glioblastoma
csc
promot
cell
prolifer
selfrenew
crosstalk
exosom
signal
transduct
surround
microenviron
exosom
releas
csc
affect
signal
transduct
nearbi
breast
cancer
cell
increas
stem
breast
cancer
cell
similarli
fibroblastderiv
exosom
contribut
chemoresist
promot
colorect
csc
growth
exosom
tme
promot
transform
noncsc
csc
cafderiv
exosom
significantli
increas
abil
form
mammari
globul
promot
stem
breast
cancer
cell
similarli
cafderiv
exosom
also
promot
sphere
format
colorect
cancer
cell
activ
wnt
signal
ultim
increas
percentag
csc
exosom
gliomaassoci
msc
increas
tumorigen
glioma
stemlik
cell
transfer
addit
exosom
regener
stem
cell
phenotyp
mediat
emt
regul
stem
cellrel
signal
pathway
wnt
pathway
notch
pathway
hh
pathway
pathway
convert
cell
csc
exosom
mani
advantag
low
immunogen
biocompat
easi
product
cytotox
easi
storag
high
drug
load
capac
long
life
becom
ideal
drug
carrier
cancer
therapi
therapeut
target
csc
agent
target
cscassoci
surfac
biomark
clinic
trial
monoclon
antibodi
mab
target
cscspecif
surfac
biomark
becom
emerg
technolog
cancer
therapi
rituximab
mab
activ
agent
treatment
follicular
lymphoma
mantlecel
lymphoma
seriou
advers
reaction
still
occur
subsequ
improv
avail
afford
radioimmunotherapi
refractori
recurr
nonhodgkin
lymphoma
nhl
phase
ii
clinic
trial
radioiodin
replac
rituximab
carri
show
respons
rate
complet
remiss
rate
patient
two
case
grade
iv
hematolog
toxic
observ
encouragingli
alemtuzumab
human
antibodi
approv
treatment
chronic
lymphocyt
leukemia
cll
patient
fail
respond
alkyl
agent
purin
furthermor
combin
antibodi
treatment
refractori
cll
safe
nontox
feasibl
posit
anoth
antibodi
drug
relabel
bivatuzumab
mab
found
safe
use
treatment
head
neck
scc
result
obtain
subsequ
clinic
research
safeti
efficaci
studi
unfortun
stage
dose
escal
studi
antibodi
one
patient
head
neck
scc
esophagu
suffer
deadli
skin
toxic
sever
antibodi
develop
design
biospecif
effect
talacotuzumab
also
effect
anoth
antibodi
use
treat
relaps
refractori
highrisk
acut
myeloid
leukemia
aml
display
antileukem
activ
case
anoth
antibodi
use
treat
blastic
plasmacytoid
dendrit
cell
neoplasm
patient
result
show
major
posit
respons
seven
nine
patient
includ
five
complet
respons
two
partial
respons
ongo
phase
ii
studi
patient
blastic
plasmacytoid
dendrit
cell
neoplasm
demonstr
robust
singleag
activ
overal
respons
rate
latest
antibodi
csc
surfac
marker
flotetuzumab
talacotuzumab
also
clinic
studi
furthermor
sever
marker
distinguish
lsc
cell
clinic
develop
receptor
accessori
protein
ctype
lectinlik
cell
immunoglobulin
epcam
common
csc
biomark
also
receiv
attent
clinic
trial
adecatumumab
epcam
antibodi
use
patient
hormoneresist
prostat
cancer
result
show
epcamspecif
antibodi
great
clinic
potenti
catumaxomab
multifunct
mab
epcam
bind
recogn
epcam
cell
antigen
antiepcam
intraperiton
inject
catumaxomab
treat
epcamposit
ovarian
cancer
malign
ascit
shown
high
efficaci
kill
cancer
cell
reduc
format
ascit
catumaxomab
use
nonsmallcel
lung
cancer
also
good
surviv
rate
howev
type
epcam
antibodi
edrecolomab
adecatumumab
minim
efficaci
colorect
breast
cancer
combin
epcam
antibodi
chimer
antigen
receptor
cell
cart
technolog
also
use
variou
type
cancer
phase
trial
deeper
understand
csc
surfac
biomark
signific
progress
develop
antibodi
target
csc
tabl
howev
csc
surfac
phenotyp
vari
differ
patient
differ
cancer
differ
csc
popul
differ
phenotyp
might
coexist
csc
also
diverg
evolv
differ
cancer
cell
acquir
distinct
phenotyp
upon
relaps
therefor
strategi
use
clinic
trial
determin
accord
phenotyp
differ
cancer
time
combin
differ
surfac
antibodi
relev
chemotherapi
drug
achiev
ideal
therapeut
effect
agent
target
cscassoci
signal
pathway
clinic
trial
signal
pathway
regul
mainten
surviv
csc
becom
target
cancer
treatment
present
main
signal
pathway
wnt
notch
hh
signal
pathway
well
jakstat
signal
pathway
pathway
often
interact
tumor
develop
csc
consider
progress
made
earli
clinic
trial
notch
hh
pathway
inhibitor
target
wnt
pathway
proven
difficult
notch
signal
pathway
play
import
role
mainten
csc
induc
csc
differenti
abnorm
activ
notch
signal
pathway
observ
mani
cancer
leukemia
glioblastoma
breast
cancer
lung
cancer
ovarian
cancer
pancreat
cancer
colon
cancer
present
three
major
clinic
method
use
inhibit
notch
signal
secretas
inhibit
inhibitor
gsi
notch
receptor
ligand
antibodi
combin
therapi
pathway
exampl
gsi
test
clinic
trial
among
first
gsi
use
treat
cell
acut
lymphoblast
leukemia
children
phase
trial
howev
studi
termin
poor
result
also
clinic
activ
extracrani
solid
tumor
subsequ
phase
ii
trial
one
complet
respons
interdegen
astrocytoma
sd
extens
patient
differ
type
glioma
observ
well
toler
show
target
inhibit
recurr
pediatr
central
nervou
system
tumor
addit
combin
cisplatin
treatment
ovarian
cancer
docetaxel
treatment
local
advanc
metastat
breast
cancer
gemcitabin
treatment
ductal
adenocarcinoma
pancrea
shown
good
efficaci
howev
clinic
effect
minim
patient
advanc
solid
tumor
includ
metastat
pancreat
cancer
addit
anoth
select
gsi
show
good
antitumor
activ
preclin
earli
trial
good
metastat
colorect
cancer
metastat
pancreat
recurr
platinumresist
ovarian
cancer
combin
gemcitabin
temsirolimu
cediranib
capecitabin
advanc
solid
tumor
well
bevacizumab
recurr
highgrad
glioma
well
toler
modest
clinic
benefit
howev
combin
vismodegib
vismodegib
alon
patient
advanc
osteosarcoma
show
signific
differ
phase
ib
trial
third
oral
gsi
good
efficaci
desmoid
tumor
either
phase
subsequ
phase
ii
studi
preliminari
evid
clinic
efficaci
demonstr
patient
solid
tumor
well
patient
recurr
acut
cell
lymphoblast
leukemia
select
gsi
also
enter
clinic
trial
stage
result
still
need
verifi
play
vital
role
regul
tumor
angiogenesi
therefor
target
anoth
strategi
block
notch
signal
test
clinic
demcizumab
human
mab
target
block
interact
notch
receptor
test
phase
dose
escal
studi
patient
previous
treat
solid
tumor
result
shown
demcizumab
good
efficaci
solid
tumor
good
metastat
pancreat
cancer
treatment
combin
gemcitabin
abraxan
combin
demcizumab
carboplatin
pemetrex
treat
lung
cancer
denali
studi
ongo
anoth
phase
ii
studi
enoticumab
anoth
fulli
human
antibodi
promis
activ
phase
clinic
trial
advanc
solid
malign
activ
hh
signal
implic
varieti
cancer
activ
hh
signal
csc
contribut
csc
stem
chemoresist
metastat
dissemin
hh
signal
pathway
mainli
regul
target
gene
express
via
smoothen
smo
mediat
nuclear
transfer
transcript
factor
three
oral
smo
antagonist
vismodegib
sonidegib
glasdegib
approv
food
drug
administr
fda
show
signific
activ
local
advanc
metastat
basal
cell
carcinoma
well
aml
vismodegib
first
propos
hh
pathway
inhibitor
cancer
research
approv
fda
local
advanc
metastat
basal
cell
carcinoma
treatment
subsequ
phase
phase
ii
trial
target
recurr
medulloblastoma
shown
progressionfre
surviv
pf
shhmb
patient
treat
vismodegib
longer
effect
nonshhmb
patient
vismodegib
even
better
activ
patient
recurr
shhmb
patient
recurr
nonshhmb
vismodegib
also
test
metastat
colorect
cancer
pancreat
cancer
chondrosarcoma
relapsedrefractori
nhl
cll
ovarian
cancer
disappointingli
treatment
vismodegib
result
better
surviv
sonidegib
second
smo
antagonist
approv
treatment
local
advanc
basal
cell
carcinoma
recur
surgeri
radiotherapi
suitabl
surgeri
radiat
therapi
addit
result
multicent
random
doubleblind
phase
ii
trial
shown
mg
sonidegib
patient
advanc
basal
cell
carcinoma
clinic
appropri
dose
phase
studi
dose
escal
treat
smallcel
lung
cancer
patient
sonidegib
combin
cisplatin
etoposid
sustain
pf
patient
amplif
combin
phase
ii
trial
patient
recurr
medulloblastoma
result
complet
partial
respons
patient
use
cancer
treatment
phase
iii
clinic
trial
prostat
cancer
breast
cancer
recurr
ovarian
cancer
glasdegib
first
hh
pathway
inhibitor
approv
treatment
aml
patient
older
year
unabl
use
intens
induct
chemotherapi
show
good
safeti
toler
phase
trial
patient
partial
hematolog
malign
japan
phase
ii
trial
glasdegib
combin
cytarabinedaunorubicin
signific
efficaci
patient
aml
chronic
myeloid
leukemia
cml
highrisk
myelodysplast
syndrom
glasdegib
combin
lowdos
cytarabin
ldac
potenti
option
aml
patient
suitabl
intens
chemotherapi
select
smo
inhibitor
includ
taladegib
saridegib
also
enter
clinic
trial
cancer
singletarget
agent
smo
inhibitor
drug
resist
problem
reduc
problem
novel
inhibitor
termin
compon
hh
signal
pathway
develop
arsen
trioxid
ato
wnt
signal
pathway
associ
tumor
develop
breast
cancer
ovarian
cancer
esophag
squamou
cell
cancer
colon
cancer
prostat
cancer
lung
cancer
sever
drug
aim
wnt
signal
pathway
clinic
trial
major
wnt
inhibitor
preclin
test
clinic
data
initi
trial
shown
ipafricept
firstinclass
recombin
fusion
protein
antagon
wnt
signal
howev
role
patient
desmoid
cancer
germ
cell
cancer
neglig
ipafricept
combin
abpaclitaxel
gemcitabin
patient
untreat
stage
iv
pancreat
cancer
ipafricept
combin
paclitaxel
carboplatin
patient
recurr
platinumsensit
ovarian
cancer
ipafricept
combin
sorafenib
patient
hcc
current
investig
inhibitor
inhibit
interact
transcript
coactiv
safeti
efficaci
test
patient
advanc
myeloid
malign
advanc
metastat
pancreat
cancer
complet
phase
studi
anoth
inhibitor
activ
also
shown
effect
aml
phase
clinic
studi
recurr
refractori
myeloma
phase
iii
clinic
studi
wnt
signal
inhibitor
also
clinic
trial
includ
addit
mitochondri
glycolysi
pathway
also
play
key
role
regul
prolifer
apoptosi
csc
venetoclax
inhibitor
initi
approv
fda
recent
show
good
toler
activ
aml
patient
advers
reaction
two
arachidon
inhibitor
might
potent
agent
target
lsc
cml
shown
tabl
abnorm
signal
pathway
also
found
csc
jakstat
signal
pathway
independ
rather
form
complex
signal
network
agent
target
cscassoci
signal
pathway
ongo
clinic
trial
list
tabl
target
csc
microenviron
csc
microenviron
contribut
selfrenew
differenti
csc
regul
csc
fate
provid
cue
form
secret
factor
cell
contact
found
cancer
especi
csc
wellcharacter
drugtarget
plerixafor
drug
effect
hematopoiet
stem
cell
mobil
patient
multipl
myeloma
nhl
treatment
relaps
refractori
aml
result
patient
complet
remiss
without
white
count
recoveri
phase
iii
studi
addit
plerixafor
highdos
cytarabin
etoposid
treatment
children
relaps
refractori
acut
leukemia
myelodysplasia
syndrom
result
two
patient
complet
remiss
one
patient
incomplet
hematolog
recoveri
patient
phase
studi
small
cyclic
peptid
potent
select
antagonist
well
toler
seriou
advers
event
phase
trial
howev
combin
sunitinib
patient
metastat
renal
cell
carcinoma
better
effect
sunitinib
alon
phase
ii
trial
combin
carboplatinetoposid
patient
extens
smallcel
lung
cancer
also
signific
effect
compar
carboplatinetoposid
alon
phase
ii
studi
combin
drug
glioma
multipl
myeloma
also
clinic
trial
microenviron
play
import
role
csc
growth
also
promis
target
treatment
agent
target
microenviron
ongo
clinic
trial
list
tabl
earli
twentieth
centuri
paul
ehrlich
first
propos
idea
intact
immun
system
suppress
tumor
develop
advanc
cancer
therapi
present
emerg
immunooncolog
approach
base
understand
cellular
immun
regul
new
method
cancer
treatment
emerg
addit
antibodi
csc
molecul
mention
novel
anticsc
immunotherapeut
approach
immunolog
checkpoint
block
cart
cell
therapi
develop
drug
target
immun
checkpoint
receptor
nivolumab
pembrolizumab
cemiplimab
avelumab
durvalumab
atezolizumab
also
clinic
trial
ipilimumab
antibodi
approv
fda
initi
clinic
result
show
good
effect
patient
metastat
melanoma
cart
cell
therapi
shown
tabl
epcam
aldh
use
cscdirect
immunotherapi
recruit
conclud
csc
small
popul
cancer
cell
selfrenew
capac
differenti
potenti
therebi
confer
tumor
relaps
metastasi
heterogen
multidrug
resist
radiat
resist
sever
pluripot
transcript
factor
includ
nanog
myc
intracellular
signal
pathway
includ
wnt
notch
hh
jakstat
tgfsmad
ppar
well
extracellular
factor
includ
vascular
nich
hypoxia
tam
caf
cancerassoci
msc
ecm
exosom
essenti
regul
csc
drug
vaccin
antibodi
cart
cell
target
pathway
also
develop
target
csc
importantli
mani
clinic
trial
csc
also
perform
show
promis
futur
cancer
therapi
howev
also
multipl
hurdl
need
solv
effect
elimin
csc
first
characterist
mani
csc
specif
type
tumor
well
identifi
second
sinc
studi
csc
perform
immunedefici
mice
absenc
adapt
immun
system
model
recapitul
biolog
complex
tumor
clinic
third
csc
exist
specif
nich
sustain
surviv
howev
isol
csc
use
current
studi
lack
microenviron
fourth
environment
factor
csc
nich
well
understood
relationship
tamscaf
csc
well
studi
fifth
sinc
csc
also
share
signal
pathway
normal
stem
cell
regulatori
factor
contribut
csc
appropri
use
therapeut
target
cancer
treatment
sixth
whether
csc
activ
arrest
open
question
cancer
therapi
seventh
novel
signal
regulatori
level
rna
edit
epigenet
cellular
metabol
consid
cancer
therapi
also
contribut
stem
csc
eighth
inhibitor
target
csc
signal
specif
new
inhibitor
need
design
ninth
natur
product
target
csc
also
studi
futur
final
target
cancer
stem
cell
pathway
cancer
therapi
yang
et
al
